Skip Navigation
Department of Health and Human Services www.hhs.gov
 
Slide Tray
0 slides

Return to Slide Library

Slides

Add Presentation to Slide Tray Presentation:

First- and Second-Generation Antipsychotics for Children and Young Adults

Slide: 25 of 43

Summary of Results: Efficacy of Antipsychotics in Placebo Comparisons (2 of 2)

For the second-generation antipsychotics (SGAs) studied in pediatric use:

  • Risperidone and ziprasidone improve tics in Tourette’s syndrome. The strength of evidence for this conclusion is moderate.
  • Risperidone improves behavioral symptoms and clinical global impressions of attention deficit hyperactivity disorder/disruptive behavior disorders. The strength of evidence for this conclusion is moderate.
  • SGAs improve behavioral (irritability, an approved indication), obsessive-compulsive, and autistic symptoms of pervasive developmental disorders. The strength of evidence for this conclusion is low.